Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Luckman

Gastroenterology Plantation, FL Medical Doctor

NPI 1225001472 CMS profile 146508

8329 W Sunrise Blvd, Plantation, FL 33322

Open in the dashboard

General payments

$6,103

270 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gary Luckman of Plantation, FL is reported in the CMS Open Payments database as having received $6,103 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $912 36
2024 General $1,220 51
2023 General $759 41
2022 General $467 27
2021 General $448 28
2020 General $925 34
2019 General $1,371 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Luckman
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Gary Luckman were reported at $912. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Gary Luckman Gastroenterology median Middle half National median
2019 $1,371 $417 $126–$1,100 $163
2020 $925 $224 $74–$624 $114
2021 $448 $352 $106–$1,054 $132
2022 $467 $448 $129–$1,270 $149
2023 $759 $533 $150–$1,390 $160
2024 $1,220 $605 $160–$1,606 $164
2025 $912 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,693 81 payments
  2. Janssen Biotech, Inc. $954 44 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $509 24 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $342 19 payments
  5. Celgene Corporation $262 16 payments
  6. Intra-Sana Laboratories $250 1 payment
  7. Janssen Scientific Affairs, LLC $242 2 payments
  8. Madrigal Pharmaceuticals $225 7 payments
  9. Lilly USA, LLC $184 8 payments
  10. Intercept Pharmaceuticals, Inc. $175 9 payments
  11. Other $1,267 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,769 268 payments
  2. Honoraria $250 1 payment
  3. Education $84 1 payment
Products named General payments · program years 2019–2025
  1. STELARA $1,077 42 payments
  2. HUMIRA $447 22 payments
  3. LINZESS $360 21 payments
  4. SIMPONI $360 17 payments
  5. CREON $340 17 payments
  6. XIFAXAN $335 19 payments
  7. ENTYVIO $309 14 payments
  8. RINVOQ $308 16 payments
  9. ZEPOSIA $262 16 payments
  10. TREMFYA $253 9 payments
  11. Other $3,724 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

2,478

Median for Gastroenterology: 569

Drug cost

$185,479

Median for Gastroenterology: $104,976

Branded share of claims

22.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 39 $42,529
Ozempic Semaglutide Brand 35 $28,287
Jardiance Empagliflozin Brand 32 $24,094
Xarelto Rivaroxaban Brand 18 $21,342
Linzess Linaclotide Brand 13 $14,279
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 55 $9,369
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 11 $7,304
Mesalamine Generic 26 $7,146
Omeprazole Generic 273 $4,808
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 48 $3,482

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$39,880

Medicare's payments for the services billed

Medicare patients

185

Average age 76

Services billed

592

91 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 42%
Diabetes 37%
Chronic kidney disease 36%
Atrial fibrillation 28%
Cancer 25%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $202
$202 — —
RESMETIROM
  • Madrigal Pharmaceuticals $113
$113 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $98
$98 — —
TREMFYA
  • Janssen Biotech, Inc. $89
$89 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $87
$87 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record